Evogene (EVGN) Price to Sales (2012 - 2026)

Evogene has disclosed Price to Sales across 15 years of filings, most recently posting 11.05 for Q2 2026.

• In Q2 2026, Price to Sales fell 29.21% year-over-year to 11.05; the TTM figure through Jun 2026 stood at 2.93 (up 116.81% YoY), while the FY2025 annual figure was 2.74, up 25.33% from the prior year.
• Price to Sales came in at 11.05 for Q2 2026 at Evogene, down from 20.1 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 225.83 in Q1 2022 to a low of 3.48 in Q1 2025.
• Average Price to Sales over 5 years is 45.41, with a median of 27.19 recorded in 2025.
• Year-over-year, Price to Sales plunged 91.24% in 2023 and jumped 478.29% in 2026.
• Over 5 years, Price to Sales stood at 43.76 in 2022, then soared by 67.99% to 73.51 in 2023, then sank by 89.26% to 7.9 in 2024, then surged by 286.84% to 30.54 in 2025, then sank by 63.8% to 11.05 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 11.05 in Q2 2026, 20.1 in Q1 2026, and 30.54 in Q4 2025.